|

EXELIXIS INC (EXEL)

US30161Q1040 - Common Stock

22  +0.01 (+0.05%)

After market: 22 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

EXELIXIS INC

NASDAQ:EXEL (12/8/2023, 7:00:02 PM)

After market: 22 0 (0%)

22

+0.01 (+0.05%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap6.84B
Shares
PE78.57
Fwd PE24.04
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

EXEL Daily chart

Company Profile

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,223 full-time employees. The company went IPO on 2000-04-11. The firm is engaged in developing medicines and combination regimens at the forefront of cancer care. The company has four products, including its flagship molecule, cabozantinib, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Company Info

EXELIXIS INC

1851 Harbor Bay Parkway

Alameda CALIFORNIA 94502

P: 16508377000.0

CEO: Michael M. Morrissey

Employees: 1223

Website: https://www.exelixis.com/

EXEL News

News Image3 days ago - Exelixis, Inc.Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
News Image6 days ago - Exelixis, Inc.Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
News Image6 days ago - Arcus BiosciencesExelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
News Image10 days ago - Market News VideoTop Buys by Directors: Johnson's $2.6M Bet on EXEL
News Image11 days ago - FinancialNewsMediaImproving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END

News Image11 days ago - USA News GroupImproving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

/PRNewswire/ -- USA News Group - According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this...

EXEL Twits

Here you can normally see the latest stock twits on EXEL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example